Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression.

Find People
Find Everything
About This Site
Edit My Profile
Export RDF
Login to Profiles

Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression.

Gutiontov SI, Choe KS, Miller JL, Liauw SL. Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. Cancer Med. 2020 07; 9(13):4667-4675.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Androgen Antagonists
Anticoagulants
Disease Progression
Follow-Up Studies
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors
Platelet Count
Prostate-Specific Antigen
Prostatic Neoplasms
Radiotherapy Dosage
Risk
Time Factors
Treatment Outcome

authors with profiles

Stanley Liauw